{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:14:24Z","timestamp":1740460464085,"version":"3.37.3"},"reference-count":36,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2022,10,3]]},"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1183\/13993003.01808-2022","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T16:42:57Z","timestamp":1671122577000},"page":"2201808","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["A leap towards personalised therapy of acute lung injury"],"prefix":"10.1183","volume":"60","author":[{"given":"Martin","family":"Witzenrath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9947-7356","authenticated-orcid":false,"given":"Tobias","family":"Welte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"2024102007255623000_60.6.2201808.1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"Matthay","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2024102007255623000_60.6.2201808.2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-2778-x"},{"key":"2024102007255623000_60.6.2201808.3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","article-title":"Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials","volume":"2","author":"Calfee","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024102007255623000_60.6.2201808.4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-211090"},{"key":"2024102007255623000_60.6.2201808.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201603-0645OC"},{"key":"2024102007255623000_60.6.2201808.6","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209719"},{"key":"2024102007255623000_60.6.2201808.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02725-2021"},{"key":"2024102007255623000_60.6.2201808.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0602-4"},{"key":"2024102007255623000_60.6.2201808.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25030-7"},{"key":"2024102007255623000_60.6.2201808.10","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.cell.2020.08.001","article-title":"Severe COVID-19 is marked by a dysregulated myeloid cell compartment","volume":"182","author":"Schulte-Schrepping","year":"2020","journal-title":"Cell"},{"key":"2024102007255623000_60.6.2201808.11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200652"},{"key":"2024102007255623000_60.6.2201808.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.04.013"},{"key":"2024102007255623000_60.6.2201808.13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102007255623000_60.6.2201808.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02384-2020"},{"key":"2024102007255623000_60.6.2201808.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04165-2020"},{"key":"2024102007255623000_60.6.2201808.16","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1016\/j.cell.2021.11.033","article-title":"SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis","volume":"184","author":"Wendisch","year":"2021","journal-title":"Cell"},{"key":"2024102007255623000_60.6.2201808.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00459-2022"},{"key":"2024102007255623000_60.6.2201808.18","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Mart\u00ednez C , Mart\u00edn-Vicente P , de O\u00f1a JG , et al. Transcriptomic clustering of critically ill COVID-19 patients. Eur Respir J 2022; in press [https:\/\/doi.org\/10.1183\/13993003.00592-2022]. doi:10.1183\/13993003.00592-2022","DOI":"10.1183\/13993003.00592-2022"},{"key":"2024102007255623000_60.6.2201808.19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cels.2020.05.012","article-title":"Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection","volume":"11","author":"Messner","year":"2020","journal-title":"Cell Syst"},{"key":"2024102007255623000_60.6.2201808.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00803-2022"},{"key":"2024102007255623000_60.6.2201808.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"2024102007255623000_60.6.2201808.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01499-z"},{"key":"2024102007255623000_60.6.2201808.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433"},{"key":"2024102007255623000_60.6.2201808.24","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102007255623000_60.6.2201808.25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S2213-2600(21)00494-X","article-title":"Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial","volume":"10","author":"Temesgen","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102007255623000_60.6.2201808.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105911"},{"key":"2024102007255623000_60.6.2201808.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.134304"},{"key":"2024102007255623000_60.6.2201808.28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085231"},{"key":"2024102007255623000_60.6.2201808.29","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00031.2015"},{"key":"2024102007255623000_60.6.2201808.30","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","article-title":"Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Aman","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102007255623000_60.6.2201808.31","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2213-2600(22)00052-2","article-title":"Long-term clinical outcomes of COVID-19 patients treated with imatinib","volume":"10","author":"Duijvelaar","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102007255623000_60.6.2201808.32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00780-2022"},{"key":"2024102007255623000_60.6.2201808.33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1164\/rccm.201708-1733OC","article-title":"Prognostic and pathogenic role of angiopoietin-1 and -2 in pneumonia","volume":"198","author":"Gutbier","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102007255623000_60.6.2201808.34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13054-017-1851-6","article-title":"Vasculotide reduces pulmonary hyperpermeability in experimental pneumococcal pneumonia","volume":"21","author":"Gutbier","year":"2017","journal-title":"Crit Care"},{"key":"2024102007255623000_60.6.2201808.35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00408-020-00393-8","article-title":"Are serum interleukin 6 and surfactant protein d levels associated with the clinical course of COVID-19?","volume":"198","author":"Kerget","year":"2020","journal-title":"Lung"},{"key":"2024102007255623000_60.6.2201808.36","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.3389\/fimmu.2020.622598","article-title":"SP-A and SP-D: dual functioning immune molecules with antiviral and immunomodulatory properties","volume":"11","author":"Watson","year":"2021","journal-title":"Front Immunol"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01808-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:12:15Z","timestamp":1740377535000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01808-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12,15]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1183\/13993003.01808-2022"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01808-2022","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"type":"print","value":"0903-1936"},{"type":"electronic","value":"1399-3003"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}